Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus. Founded by Per Fischer in 2010, Minervax is backed by investors that include LF Investment, Wellington Partners, Vaekstfonden, Sanofi Ventures, and Sunstone Life Science Ventures and is headquartered in Hellerup.